Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
32 studies found for:    PITUITARY ADENOMA, ACTH-SECRETING
Show Display Options
RSS Create an RSS feed from your search for:
PITUITARY ADENOMA, ACTH-SECRETING
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Conditions: Cushing's Disease;   Corticotroph Adenoma
Intervention: Drug: Cabergoline
2 Terminated
Has Results
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
Condition: Cushing's Disease
Intervention: Drug: rosiglitazone maleate
3 Recruiting Treatment of Cushing's Disease With R-roscovitine
Condition: Cushings Disease
Intervention: Drug: R-roscovitine
4 Active, not recruiting Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: Pasireotide with or without cabergoline
5 Active, not recruiting Safety and Efficacy of LCI699 in Cushing's Disease Patients.
Condition: Cushing's Disease
Intervention: Drug: LCI699
6 Completed An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Condition: Cushing's Disease
Intervention: Drug: Pasireotide sub-cutaneous formulation
7 Recruiting Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
Condition: Cushing's Disease
Interventions: Drug: osilodrostat;   Drug: osilodrostat Placebo
8 Completed Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment
Condition: Cushing Disease
Intervention: Drug: Pasireotide 0.6 MG/ML
9 Not yet recruiting Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease
Condition: Cushing's Disease
Intervention: Device: Virtual radial task in 3D
10 Recruiting Cushing's Disease Complications
Condition: Cushing's Disease
Intervention: Other: Exams and questionnaires
11 Active, not recruiting Cushing´s Disease Epidemiology in Sweden
Condition: Cushing Disease
Intervention:
12 Recruiting Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
Condition: Cushings Disease
Intervention: Drug: SOM230
13 Recruiting Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: LCI699
14 Withdrawn Mifepristone in Children With Refractory Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: mifepristone
15 Completed Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
Condition: Cushing's Disease
Interventions: Drug: SOM230 LAR 30 mg;   Drug: SOM230 LAR 10 mg
16 Terminated Long-term Cardiovascular Risk in Cured Cushing's Patients
Condition: Cushing's Disease
Intervention:
17 Unknown  Preoperative Bexarotene Treatment for Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: Bexarotene
18 Completed
Has Results
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: Pasireotide
19 Completed Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease
Condition: Cushing Disease
Intervention: Drug: Pasireotide
20 Recruiting Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
Conditions: Pituitary Neoplasms;   Prolactinoma;   ACTH-Secreting Pituitary Adenoma;   Gigantism;   Growth Hormone-Secreting Pituitary Adenoma
Intervention: Other: Educational Intervention

   Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.